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MaBACKGROUND Prosthetic valves currently used in children lack the ability to grow with the patient and often require
multiple reoperations. Small intestinal submucosa-derived extracellular matrix (SIS-ECM) has been used successfully as a
patch for repair in various tissues, including vessels, valves, and myocardium.
OBJECTIVES This study sought to assess the remodeling potential of a tubular tricuspid valve (TV) bioprosthesis made
of SIS-ECM by evaluating its growth, structure, and function in a growing ovine model.
METHODS A total of 12 3-month-old lambs were studied for a period of 3 or 8 months. SIS-ECM TVs were placed in
8 lambs; conventional bioprosthetic valves and native valves (NV) were studied as controls. All lambs underwent serial
echocardiography, measuring annulus diameter and valve and right ventricular function.
RESULTS The SIS-ECM valves demonstrated an incremental increase in annular diameter similar to NV. SIS-ECM valve
function was normal in 7 of 8; 1 valve had severe regurgitation due to a ﬂail leaﬂet. Explanted SIS-ECM valves
approximated native tissue in gross appearance. Histopathology demonstrated migration of resident mesenchymal cells
into the scaffold and trilaminar ECM organization similar to an NV, without inﬂammation or calciﬁcation at 8 months.
Ex vivo mechanical testing of SIS-ECM valve tissue showed normalization of the elastic modulus by 8 months.
CONCLUSIONS In an ovine model, tubular SIS-ECM TV bioprostheses demonstrate “growth” and a cell-matrix structure
similar to mature NVs while maintaining normal valve function. The SIS-ECM valve may provide a novel solution for TV
replacement in children and adults. (J Am Coll Cardiol 2015;66:877–88) © 2015 by the American College of Cardiology
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878V alvular heart disease represents amajor public health problem glob-ally, and is associated with signiﬁ-
cant morbidity and mortality (1,2). Each
year, approximately 290,000 heart valve re-
placements are performed worldwide; this
number is expected to increase 3-fold by
2050 (3,4). Additionally, many aggressive
valve repair procedures are done each year
because no long-lasting valve replacement
options exist, especially in the pediatricSEE PAGE 889population. The 2 main valve replacement options,
mechanical and bioprosthetic (BP), improve survival
and quality of life but possess signiﬁcant and distinct
limitations (5,6). Mechanical valves are prone to
thromboembolic events and increased risk of serious
hemorrhage due to required anticoagulation therapy.
Because bioprostheses are more susceptible to struc-
tural valve degeneration, they lack durability, result-
ing in necessary reoperations. All of these potential
adverse events are magniﬁed in the pediatric popula-
tion, where the need for a functional valve is decades
longer than in the typical adult receiving valve
replacement. Valve replacement in pediatric patients
is further confounded by the need for small prosthetic
valve sizes and, consequently, multiple operations to
accommodate patient growth.
Small intestinal submucosa-derived extracellular
matrix (SIS-ECM) scaffolds are capable of growth andHistology and biomechanical
testing at 8 months
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, respectively. BP ¼ bioprosthetic; NV ¼ native valve;
ucosa-derived extracellular matrix.remodeling into surrounding tissues such as the
superior vena cava (7). SIS-ECM has been success-
fully used as a patch material in a wide variety of
tissues, including bladder walls and ligaments, as
well as some cardiovascular tissues, including ves-
sels, myocardium, and to a limited extent, valves
(8–17). In a small number of animals, acellular SIS-
ECM–derived tubular valves have demonstrated
early physiological remodeling (16), but the potential
for growth and durable function remains unknown.
Therefore, we hypothesized that a SIS-ECM tubular
valve in the tricuspid position has the potential to
remodel, as demonstrated by the organization of a
cell matrix architecture similar to native valve (NV)
tissue, as well as by normal growth and in vivo
function over time. The objective of this study was
to assess a tubular tricuspid valve (TV) bioprosthesis
made of SIS-ECM by evaluating its growth, cell ma-
trix architecture, and function in a growing ovine
model.
METHODS
STUDY DESIGN. Twelve lambs (mixed breed, 6
wethers and 6 ewes), approximately 3 months of age,
were included in the study (Figure 1). SIS-ECM valves
(20 mm) were implanted in 8 lambs, conventional BP
valves in 2 lambs, and NVs in 2 lambs. For tissue
collection and examination, 6 lambs were euthanized
at 3 months and the remainder at 8 months. All lambs
received humane care in compliance with The Guide
for the Care and Use of Laboratory Animals published
by the National Institutes of Health (18). All study
protocols were approved by the Cincinnati Children’s
Research Foundation Institutional Animal Care and
Use Committee.
VALVE MATERIAL AND DESIGN. SIS-ECM (CorMatrix
Cardiovascular, Roswell, Georgia) is a sheet of acel-
lular ECM derived from porcine small intestinal
submucosa. Two of the SIS-ECM ply sheets are press-
lyophilized together and shaped into a desired
tubular structure by suturing its edges together with
6-O polypropylene suture (Prolene, Ethicon US,
Somerville, New Jersey), resulting in a tubular valve
with an inner diameter of 20 mm and a length of
30 mm (Figure 2). SIS-ECM is made up of approxi-
mately 90% collagen, the majority of which is type 1
collagen that is reported to maintain 3-dimensional
architecture. It also contains glycosaminoglycans,
including heparin sulfate, chondroitin sulfate, and
hyaluronic acid (19).
The tubular SIS-ECM valve works similar to native
atrioventricular valves. Native tricuspid and mitral
valves develop in the form of a tube with dissociation
FIGURE 2 SIS-ECM Tubular Valve
Top and side views representing diameter and length of the valve. Abbreviation as in
Figure 1. Online Video 1 demonstrates a functional SIS-ECM valve after explant.
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879from the inner lining of the embryonic cardiac tube
and form chordae as they develop. External pressure
as a result of ventricular contraction on the SIS-ECM
tube collapses the tube just like a Heimlich valve.
The 3 papillary attachment points create the 3 leaﬂets
and there are no distinct leaﬂets in the tube (Online
Video 1).
SURGICAL PROCEDURES AND IMAGING. Lambs
were intubated under general anesthesia using
ketamine (5 to 15 mg/kg) and midazolam (0.02 to
0.05 mg/kg) for induction and isoﬂurane (1% to 4%)
for maintenance; vecuronium (4 to 8 mg/kg) was used
to induce paralysis as needed. A dose of ceftiofur
sodium (1 to 2.2 mg/kg) was given as antibiotic pro-
phylaxis and buprenorphine (0.005 to 0.01 mg/kg) for
analgesia before incision. A right lateral thoracotomy
was performed in the fourth intercostal space, and
the pericardium was opened anterior to the phrenic
nerve in a longitudinal fashion. Heparin (300 U/kg)
was administered and re-dosed based on activatedCENTRAL ILLUSTRATION Novel Bioprosthetic TV Demons
Zafar, F. et al. J Am Coll Cardiol. 2015; 66(8):877–88.
(A) In an ovine model, animals tripled their weight over the study perio
matrix (SIS-ECM) tricuspid valve (TV) diameter. Grossly, SIS-ECM valves
view (B); the former were populated by resident smooth muscle actin (SMclotting time before cardiopulmonary bypass. After
establishing cardiopulmonary bypass via aortobi-
caval cannulation and a cardioplegia (lidocaine–
magnesium; single dose) arrest of the heart, a righttrates Physiological Growth and Remodeling With Preserved Valve Function
d with an appropriate increase in the tubular small intestinal submucosa-derived extracellular
appeared similar to native valves (NVs) at 8 months: (top) atrial view and (bottom) ventricular
A)-positive, valvular interstitial cells with no calciﬁcation at 8 months (C). ARed ¼ Alizarin Red.
TABLE 1 TTE Data: 3-Month Cohort
Months
(Post-Operative) Regurgitation Stenosis
Annulus
Diameter
(mm)
Mean Gradient
(mm Hg) Mobility RV Function
Weight
(kg)
SIS-ECM Lamb 1 0 Mild None 20.7 2.8 Full Normal 22.7
1.5 Trivial None 23.3 1.3 Full Normal 29.8
3 Trivial None 26.7 1.4 Full Normal 40.4
Lamb 2 0 Moderate None 21.7 1.1 Full Normal 18.1
1.5 Severe None 25.2 1.8 Flail Normal 27.2
3 Severe None 26.8 2.6 Flail Normal 37.7
Lamb 3 0 Trivial None 18.3 0.9 Full Normal 18.1
1.5 Mild None 21.3 1.5 Full Normal 29.0
3 Mild None 25.0 0.3 Full Normal 38.1
Lamb 4 0 Trivial None 19.8 1.7 Full Normal 16.1
1.5 Mild None 22.4 1.6 Full Normal 34.5
3 Mild None 24.6 1.3 Full Normal 42.4
BP Lamb 5 0 Trivial None 21.5 2.8 Full Mild* 19.0
1.5 Trivial None 19.2 4.1 Full Normal 39.0
3 Trivial None 19.9 4.9 Full Normal 43.1
NV Lamb 6 0 Trivial None 20.9 1.2 Full Normal 23.1
1.5 Trivial None 22.6 0.3 Full Normal 37.0
3 Trivial None 26.7 1.0 Full Normal 51.3
*Dysfunction. Trivial to mild regurgitation as noted in Online Video 2. Severe regurgitation as noted in Online Video 3.
BP ¼ bioprosthetic; NV ¼ native valve; RV ¼ right ventricular; SIS-ECM ¼ small intestinal submucosa-derived extracellular matrix; TTE ¼ transthoracic echocardiography.
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880atriotomy was performed. The TV apparatus, in-
cluding 3 leaﬂets and all chordae tendineae, was
excised. The distal end of the SIS-ECM valve was
sutured to the 3 papillary muscles using a 5-O poly-
dioxanone or 5-O polypropylene suture with a small
supporting SIS-ECM pledget, which was introduced
with the evolving experience after the ﬁrst 2 lambs
had already undergone the procedure. The ﬁrst 2
lambs, therefore, had no pledgets used for the papil-
lary attachments, but it was felt that the suture cut
through the papillary muscle because of the repeated
stress placed on the muscle/suture interface when the
valve was functioning. Therefore, a SIS-ECM pledget
subsequently was added to distribute the force on the
tissue, a common surgical method used to address
such a concern.
The proximal end of the SIS-ECM valve was su-
tured to the TV annulus in a running fashion,
using the same suture material. Valve competence
was tested by intraoperative saline injection leak
test, and once conﬁrmed, the right atriotomy was
closed and cardiopulmonary bypass discontinued. A
right thoracotomy was closed with a drain in place,
and the lamb was allowed to recover in a cage.
Lambs received supplemental oxygen via cone
mask until vital signs were stable and they could
stand up.
All lambs underwent transthoracic echocardio-
graphic evaluation in the post-operative period, at 1.5and 3 months, and for the second cohort, at 5 and
8 months following surgery. The reader was blinded
to the valve type being evaluated for all echocardi-
ography studies. Valve size (annulus dimension) and
leaﬂet mobility (full, restricted, or ﬂail) were noted.
Valve function was assessed using established
guidelines and valve dysfunction (regurgitation or
stenosis) was classiﬁed as none, trace, mild, moder-
ate, or severe (20,21). Right ventricular function was
noted at each interval and classiﬁed as normal,
mildly, moderately, or severely depressed (22).
An extended Methods section is available in the
Online Appendix, including tissue harvesting, prep-
aration, analysis, and biomechanical testing.
STATISTICAL METHODS. Echocardiographic mea-
surements are presented as mean  SD. Continuous
data were compared using the Mann-Whitney U
nonparametric test with Bonferroni corrections for
multiple comparisons.
RESULTS
All lambs undergoing surgery recovered without
complication and survived in good health until their
scheduled euthanasia dates. There were no reopera-
tions, bleeding, or wound infections noted in any
animals, nor were there any paravalvular leaks or
valve failures noted on post-operative echocardio-
gram in any lamb. All lambs, including the native
TABLE 2 TTE Data: 8-Month Cohort
Months
(Post-Operative) Regurgitation Stenosis
Annulus
Diameter
(mm)
Mean Gradient
(mm Hg) Mobility RV Function
Weight
(kg)
SIS-ECM Lamb 7 0 Mild None 18.6 1.0 Full Normal 16.8
1.5 Mild None 22.6 1.9 Full Normal 23.4
3 Mild None 27.9 2.2 Full Normal 40.5
5 Mild None 30.8 4.5 Full Normal 48.3
8 Mild None 31.5 3.6 Full Normal 58.1
Lamb 8 0 Trivial None 20.1 0.7 Full Normal 18.6
1.5 Trivial None 25.4 1.3 Full Normal 34.3
3 Mild None 26.3 2.0 Full Normal 43.1
5 Mild None 29.7 1.5 Full Normal 46.3
8 Mild None 30.3 2.9 Full Normal 65.6
Lamb 9 0 Mild None 21.4 2.1 Full Normal 18.0
1.5 Mild None 24.4 1.1 Full Normal 31.5
3 Trivial None 26.3 1.4 Full Normal 48.6
5 Mild None 29.4 3.4 Full Normal 55.3
8 Mild None 31.1 3.0 Full Normal 71.5
Lamb 10 0 Trivial Mild 21.8 4.4 Restricted Normal 16.8
1.5 Mild None 25.3 2.4 Restricted Mild* 25.4
3 Mild None 26.4 1.7 Full Mild* 38.6
5 Mild None 27.9 2.7 Full Normal 53.8
8 Mild None 29.3 1.4 Full Normal 64.1
BP Lamb 11 0 Trivial None 19.2 3.4 Full Normal 15.5
1.5 Trivial None 20.0 4.3 Full Mild* 32.9
3 Trivial None 19.4 6.0 Full Mild 41.1
5 Trivial Mild 18.5 6.3 Full Mild 52.1
8 Trivial Mild 19.5 7.5 Restricted Moderate* 54.4
NV Lamb 12 0 Trivial None 18.0 0.6 Full Normal 18.4
1.5 Trivial None 23.7 0.9 Full Normal 34.3
3 Trivial None 27.4 0.5 Full Normal 50.1
5 Trivial None 29.7 1.7 Full Normal 67.1
8 Trivial None 32.6 2.0 Full Normal 84.5
*Dysfunction.
Abbreviations as in Table 1.
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881controls, demonstrated normal activity, appetite, and
weight gain throughout the study period.
SIS-ECM VALVE CHANGES OVER TIME. Serial trans-
thoracic echocardiography demonstrated physiolog-
ical enlargement in the SIS-ECM valves as shown by
an incremental increase in the annulus diameters
proportional to the change in weight similar to NVs
(Central Illustration). There was no change in the
annulus diameter in BP valves. Seven of 8 SIS-ECM
valves had stable trivial-to-mild regurgitation
(Online Video 2). One SIS-ECM valve had severe
regurgitation due to leaﬂet detachment from the
papillary muscle. This valve had been attached to the
papillary muscles without a pledget-reinforced suture
(Online Video 3).
All SIS-ECM valves had full mobility without ste-
nosis (transannular mean gradient 2.0 1.0 mm Hg),
and right ventricular systolic function remainednormal (Tables 1 and 2). Stable trace “physiological”
tricuspid regurgitation was also noted for all BP and
NVs. The BP valves developed stenosis by 8 months,
as evidenced by an increasing transannular mean
gradient (4.9  1.6 mm Hg), as the sheep grew
and gained weight, which was signiﬁcantly higher
compared with SIS-ECM valves (p ¼ 0.004). The
mean transannular gradient for the BP valve animal
was 7.5 mm Hg at 8 months with restricted leaﬂet
mobility (Table 2). Similarly, transannular velocity
for SIS-ECM valves (0.68  0.18 m/s) was similar to
NVs (0.48  0.15 m/s; p ¼ 0.06); however, it was
lower compared with the BP valve (1.1  0.16 m/s;
p ¼ 0.004).
At 8 months, SIS-ECM valves had a similar ap-
pearance to NVs: grossly, they looked as if there were
3 leaﬂets attached to papillary muscles by rudimen-
tary chordae tendineae (Figure 3). The margins of the
SIS-ECM valve were integrated into the surrounding
FIGURE 3 Gross Appearance of Explanted Valve
The explanted valve is seen at 3 and 8 months from atrial (A) and ventricular (B) views. Abbreviations as in Figures 1 and 2.
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882tissue at both the annulus and papillary muscles.
There was no evidence of gross thrombosis or calci-
ﬁcation. One SIS-ECM valve had a papillary detach-
ment noted at the 1.5-month echocardiogram
(Figure 4). This failure was attributed to a technical
failure secondary to not using a SIS-ECM pledgetted
suture to attach the valve to the papillary muscle.
Composite images of the entire TV leaﬂets show
the SIS-ECM valve to be largely acellular with
unorganized ECM after 3 months, but densely
cellular with stratiﬁed ECM approximating normalFIGURE 4 Gross Abnormality in SIS-ECM Valve Explant
A detached papillary muscle was noted in a small intestinal
submucosa-derived extracellular matrix (SIS-ECM) valve.architecture after 8 months (Figure 5). This is evi-
denced by separation of collagen, elastin, and pro-
teoglycan layers restricted to the leaﬂet’s proximal,
nonapposing aspect (Figure 5). Interestingly, the
proximal aspect of the 3-month SIS-ECM valve shows
migration of resident smooth muscle actin (SMA)-
positive valve interstitial cells (VICs) into the scaffold
with elongated cell morphology during constructive
remodeling, but a return to normal VIC morphology
after 8 months, suggesting transition from remodel-
ing to homeostasis (23,24). Of note, ﬁbroblast
morphology at 3 months by ultrastructure electron
microscopy was abnormal, demonstrating elongated
spindles that normalized by 8 months, during which
time collagen ﬁbers increased and organized
(Figure 6). Qualitatively, the vast majority of cells
were resident cells that migrated in from the annular
margin. After 3 months, there was partial endotheli-
alization of the SIS-ECM valve demonstrated by CD31
staining. At 8 months, this endothelialization was
complete on the valve surface and there was evi-
dence of ongoing remodeling in that interstitial cells
stained positive for CD31. There was nominal evi-
dence of inﬂammation as demonstrated by small
clusters of macrophages at both 3 and 8 months post-
implantation (Figure 6), mostly around the suture
areas, suggesting an injury mechanism with little
evidence of inﬁltration of the macrophages by he-
matoxylin and eosin staining (data not shown).
Fetal liver kinase 1 (vascular endothelial growth fac-
tor receptor 2; FLK1 [VEGFR2]) demonstrated
increased expression in the interstitium, especially
FIGURE 5 Valve Architecture
Movat pentachrome sections are reconstructed to show the entire length of the NV (A), 3-month SIS-ECM (B), and 8-month SIS-ECM (C),
leaﬂets from the insertion of the annulus (left) to the free edge (right) with the line of coaptation identiﬁed by an arrow. The 3-month BP
shows gross differences between the proximal (left) and distal (right) halves of the leaﬂet, including the repopulation of the proximal half with
cells and early matrix remodeling. Abbreviations as in Figure 1.
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883surrounding neovessels. Likewise, there was only
trace mineralization, without gross calciﬁcation, at 3
months and none at 8 months (Figure 6).
Among NVs, the elastic Young’s modulus was low at
3 months after implantation (6 months of age)
(Figure 7), as compared with the value for the Young’s
modulus of a normal adult valve (Figure 7, dashed
line). The elastic modulus of the SIS-ECM valves was
similar to the normal adult valve value at both time
points. Tissue stiffness was similar in the proximal and
distal regions in both SIS-ECM and NVs at both
3 months and 8 months (data not shown). These re-
sults demonstrate that at 8 months post-implantation
(11 months of age), the SIS-ECM valves have both
physiological valve biomechanical properties and
normal mature ECM architecture (Figures 5 and 6).DISCUSSION
Tubular SIS-ECM valves increase in size proportional
to the sheep’s somatic growth, whichwas similar to the
normal growth of NVs in control animals. By the end of
the study, sheep gained more than 3 times their orig-
inal weight, their valve annulus showed a 50% increase
in size (average 10 mm), and the valve remained
physiologically functional (Central Illustration). His-
tologically, SIS-ECM valves demonstrated scaffold
population with resident VICs and ongoing matrix
remodeling, as evidenced by cellular morphology and
ECM organization approximating normal valves over
time. The tubular SIS-ECMvalve has the potential to be
a durable valve replacement option for patients with
valvular heart diseases. Currently, severe valvular
FIGURE 6 Microscopic Histopathologic Analysis
Continued on the next page
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FIGURE 7 Valve Elasticity
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The BP scaffold remained relatively stiff at 3 months as
compared with native young valves (dotted line), but normalized
by 8 months, with values for Young’s modulus similar to
the value of the native adult valve (dashed line), temporally
corresponding with transformation of the cell matrix organiza-
tion to approximate native architecture. Values are average 
SEM. Abbreviations as in Figure 1.
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885heart diseases lack a pharmacological treatment, and
surgery remains the only effective management, but
even that approach remains suboptimal (25). Despite
signiﬁcant improvements in prosthetic valves and
surgical techniques, these have not proven to be a cure.
Instead, NV disease is often traded for prosthetic valve
disease. Nakano et al. (26) reported a 10-year risk of
30% for valve-related events after TV replacements.
This outcome worsens for pediatric patients, with
survival of only 57% and freedom from repeat valve
replacement of 25% at 20 years following aortic valve
replacements (27). Taken together, current valve
replacement options are inadequate for treating
valvular heart diseases, particularly in children.Histochemistry (A–C and S–U), immunohistochemistry (D–F and J–R), an
and S) and SIS-ECM valves explanted after 3 (B, E, H, K, N, Q, and T) an
shows normal ECM organization with all sections oriented such that the
layered stratiﬁcation in 3- and 8-month SIS-ECM valves. Resident cells
that demonstrate a smooth muscle actin (SMA)-positive ﬁbroblast-like e
leaﬂet at 8 months with quiescent morphology (F, arrows). These obse
smooth muscle cell ﬁbroblast–like morphology (asterisks, G and I) and
lialization of the SIS-ECM valve at 3 months (K), predominantly on the
liver kinase (FLK) is shown in the NV restricted to the endothelium as exp
in areas with neovascularization (N and O). There is nominal evidence of
Alizarin Red (ARed) (T and U). Arrows in D, J–O, Q, R, T and U indicate
magniﬁcation. Abbreviations as in Figure 1.
FIGURE 6A signiﬁcant limitation to currently available valve
replacements is their failure to accommodate somatic
growth in the pediatric population, and as a result,
these valves undergo nonstructural valve failure
(28,29). Surgeons have oversized these valves in an
attempt to accommodate for this problem; however,
patient-to-valve size mismatch has been shown
repeatedly to have worse outcomes (30,31). Conven-
tional BP valves in this study demonstrated no
change in annular size and increasing transvalvular
gradient with increase in weight of the lambs even-
tually resulting in stenosis and immobile leaﬂets,
which is consistent with clinical studies (32,33). The
tubular SIS-ECM valves have demonstrated growth,
therefore accommodating change in annulus diam-
eter (>50% increase) with a more than 3-fold increase
in weight over the study period. This character-
istic is vital for pediatric patients because patient
growth guarantees their need for re-replacement with
current prosthetic valves. With no anticoagulation
needed, tubular SIS-ECM valves may also be a valid
option for adults, particularly young adults wishing
to avoid reoperations. Growth here refers to the
change in annulus diameter with the change in ani-
mal weight; however, whether this is the same pro-
liferative process as in an NV is unclear. Long-term
studies are currently underway in our lab to further
evaluate cellular proliferation and matrix changes in
SIS-ECM valves to see whether true growth can be
demonstrated.
Calciﬁcation is the most common reason of BP
valve failure (34). Saleeb et al. (35) demonstrated
only an 18% freedom from valve failure after 3 years
of aortic valve replacement. In this experience, a
bovine pericardial BP valve was used, and they
demonstrated accelerated degeneration with diffuse
intrinsic leaﬂet calciﬁcation with virtually immobile
leaﬂets (35). We have noted only minimal calciﬁca-
tion at 3 months and none at 8 months, with alld electron microscopy (EM) (G–I) are shown in NVs (A, D, G, J, M, P,
d 8 (C, F, I, L, O, R, and U) months. (A–C) Movat pentachrome (Pent)
ﬁbrosa layer is at the top of the panel in NV and approximation of
populate the proximal end of the scaffold at 3 months with cells
longated morphology (E, arrows) that extend to populate the entire
rvations are supported by ultrastructural analysis (H and I), showing
spindle-shaped SMC (arrow, H). CD31 demonstrates partial endothe-
atrialis side of the valve, and more completely at 8 months (L). Fetal
ected (M), but is seen in the interstitium at 3 and 8 months, including
inﬂammation as seen by CD68 (Q and R) or mineralization as seen by
positive staining. All histopathologic images are at 10 or 20
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Similarly, a few small areas of inﬂammation were
noted, mostly around suture areas, which is a known
problem with polypropylene suture. This is surpris-
ing because the juvenile ovine model (#20 weeks at
implant) is used to analyze calciﬁcation predilection
in BP valves. In this model, such calciﬁcation is seen
as early as 3 weeks post-implant, and in some valves,
calcium content increases within days of implant;
the average time to signiﬁcant calciﬁcation of BP
valves is 3 months post-implant (36,37). The SIS-ECM
valve appears to be less prone to calciﬁc degener-
ation than commonly seen in currently available
BP valves.
This study demonstrated that the expression of
alpha-SMA (alpha-SMA) was similar when comparing
NVs with 3- and 8-month SIS-ECM valves, suggesting
alpha-SMA-positive VICs are not activated as part
of a disease process, and the favorable remodeling
process we observed in the SIS-ECM valves is
not mediated by the alpha-SMA VIC population.
SIS-ECM demonstrated partial endothelialization of
the scaffold with a small population of CD31-positive
endothelial cells invading the interstitium at 3
months and more so by 8 months. This phenomenon
resembles a nonpathological epithelial–mesenchymal
transition–like process seen in embryonic (pre-natal)
development, where endothelial cells acquire the
migratory characteristics of mesenchymal cells and
form organized tissue during development (38). This
is also indicated by presence of interstitial CD31 cells
and neovessel formation (VEGFR2-positive cells),
consistent with processes resembling fetal wound
healing (39). Taken together, this suggests that
reactivated EMT may contribute to the remarkable
post-natal remodeling that occurs in this SIS-ECM BP
tissue. Further studies are needed to establish un-
derlying mechanisms.
SIS-ECM valves are stiffer at 3 months compared
with the NV, but demonstrate physiological stiffness
similar to NV stiffness by 8 months, corresponding
temporally with the changes in ECM architecture
of the NV during growth. Valve elasticity changes
over time in humans, pigs, and sheep, because they
have more elastin ﬁbers in fetal life and early age;
however, with aging, elastin ﬁbers are surrounded
by more collagen ﬁbers, reducing elasticity and
increasing stiffness (40,41). The distal half of the
valve leaﬂets lacks organization, which is consistent
with progressive remodeling. Because there is no
disease in these valves, we do not think this repre-
sents pathology. This observation is consistent with
a lack of remodeling in the more distal aspect
of the valve (i.e., with the remodeling processoriginating at the attachment point to native tissue
and working its way from annulus to tip). Alterna-
tively, this observation may reﬂect different regions
of the valve experiencing different biomechanical
stresses because the free edge of the valve experi-
ences less shear. Normal in vivo (echo) and ex vivo
(biomechanics) tissue function at 8 months post-
implant suggests that the remodeling processes
appear to be adaptive and durable. Further, ECM or-
ganization in the SIS-ECM BP is promising, but
mechanisms of ongoing tissue homeostasis and
potential for structural degeneration need to be
examined more closely. This is being evaluated by
long-term ($2 years) SIS-ECM TV implants in the
ovine model, which are already in the post-implant
observational stage in our lab.
STUDY LIMITATIONS. Due to using a large animal
model, this study involved a relatively small number of
animals. Therefore, some of the observations are
limited to qualitative inferences, rather than statistical
and quantitative conclusions. Leaﬂet lengths were not
compared because this information was not consistent
across the NVs due to the presence of well-formed
chordae. Although the tissue analysis showed various
valve-like cells and macrostructure, with no signiﬁ-
cant inﬂammation component apparent, the presence
of various nonresident cells was not examined.
Another important limitation of this study is the dif-
ference in coagulation cascades of ovine species from
humans. Though there was no post-cardiopulmonary
bypass anticoagulation used in these animals and no
thrombotic events or valvular thrombosis noted, these
results need to be cautiously interpreted.
Despite these limitations, this study demonstrated
that SIS-ECM valves are capable of remodeling and
growth, with intact valve function, in a rapidly
growing animal model. Further studies to delineate
the origin of these cells into the ECM, signals that
modulate this remodeling, and valve examination
over an extended period of time will help improve
design and applications of the SIS-ECM valves. There
are several unpublished reports of clinical use of
SIS-ECM valves in young adults outside and on
compassionate use basis inside the United States.
Furthermore, phase I human studies are being
considered by the U.S. Food and Drug Administration
to examine the safety of these SIS-ECM bio-prosthe-
ses in the tricuspid position.
CONCLUSIONS
SIS-ECM valves demonstrated a potential to “grow”
with the animal while maintaining normal valve
function. The SIS-ECM valve also developed a cellular
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The long-term
success of valve replacement in patients with valvular heart
disease is limited by structural degeneration of biological pros-
theses or need for continuous anticoagulation with mechanical
devices, and when implanted in young patients, somatic growth
typically requires reoperation. Tubular valves formed from SIS-
ECM have shown growth in an animal model.
TRANSLATIONAL OUTLOOK: Further studies are needed to
delineate the origin of the cells populating the ECM, understand
the signals that modulate its remodeling, and evaluate the
properties of valves created from SIS-ECM with respect to ca-
pacity for continued growth, and resistance to thrombosis,
calciﬁcation, and structural degeneration over extended periods.
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887and matrix structure, as well as mechanical properties
similar to the native ovine valve, which is unique
for a BP valve demonstrating no calciﬁcation. The
SIS-ECM valve bioprosthesis offers the potential to
alleviate some of the limitations of current valve
therapies by perhaps providing a novel solution for
TV replacement in children and adults.
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